Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

55.27 -0.84 (-1.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,539,785
Open 56.08
Bid (Size) 55.00 (1)
Ask (Size) 55.55 (1)
Prev. Close 56.11
Today's Range 55.15 - 56.35
52wk Range 52.93 - 94.85
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
A volatile stock market represents an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Stocks
Exposures COVID-19 US Equities
1 Mid-Cap Stock with Exciting Potential and 2 to Avoid
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory

Performance

YTD
-16.9%
-16.9%
1 Month
-12.2%
-12.2%
3 Month
-19.9%
-19.9%
6 Month
-15.1%
-15.1%
1 Year
-25.7%
-25.7%

More News

Read More
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching
Via Chartmill
Top movers in Friday's after hours session
Via Chartmill
Earnings Scheduled For May 1, 2025
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
From Brodsky & Smith LLC
Via GlobeNewswire
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
Via Stocktwits
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover
Via Investor's Business Daily
Exposures Product Safety
BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress
Via StockStory
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching
Via Chartmill
1 Healthcare Stock with Competitive Advantages and 2 to Brush Off
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know
Via Benzinga
A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings
Via Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets
Via StockStory
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
2 Cash-Producing Stocks with Exciting Potential and 1 to Question
Via StockStory
1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question
Via StockStory
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is an undervalued gem with solid fundamentals.
Via Chartmill
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
Via The Motley Fool
Topics Government Stocks World Trade
Exposures COVID-19 Political Tariff
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Frequently Asked Questions

Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?
Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?
BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?
The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market
What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?
The current price of BioMarin Pharmaceutical Inc. - Common Stock is 55.27
When was BioMarin Pharmaceutical Inc. - Common Stock last traded?
The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 06/05/25 04:00 PM ET
What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?
The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 10.13B
How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?
BioMarin Pharmaceutical Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.